Methods for altering mrna splicing and treating familial dysautonomia and other mechanistically related disorders
CA 2540681 C · Owner: The General Hospital Corporation · Inventors: Gusella, James F.; Slaugenhaupt, Susan A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to methods for altering the splicing of mRNA in cells. In particular, this invention also relates to methods for increasing the ratio of wild type to misspliced forms of mRNA and corresponding encoded proteins in cells possessing a mutant gene encoding either the i) misspliced mRNA corresponding to the mutant protein or ii) a component in the splicing machinery responsible for processing the misspliced mRNA. In addition this , invention relates to treating individuals having a disorder associated with a misspliced mRNA, such as Familial Dysautonomia or Neurofibromatosis 1 by , administering to such an individual a cytokinin such as kinetin.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 1, 2004 and granted August 12, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 1, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 1, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.